SMMT vs. UTHR: Summit Therapeutics vs. United Therapeutics Stock Comparison

November 11, 2026

How do Summit Therapeutics (SMMT) and United Therapeutics (UTHR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Summit Therapeutics (SMMT) and United Therapeutics (UTHR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for Summit Therapeutics (SMMT) and United Therapeutics (UTHR)
Profile Item	SMMT	UTHR
Name	Summit Therapeutics Inc.	United Therapeutics Corporation
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Biotechnology
GICS Sub-Industry	Biotechnology	Biotechnology
Market Capitalization	13.06 billion USD	23.94 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	March 5, 2015	June 17, 1999
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

SMMT

UTHR

GSPC

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Summit Therapeutics (SMMT) and United Therapeutics (UTHR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Summit Therapeutics (SMMT) and United Therapeutics (UTHR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Summit Therapeutics (SMMT) and United Therapeutics (UTHR)
Metric	SMMT	UTHR
Total Return (1Y)	-2.48%	28.77%
Total Return (3Y, Annualized)	116.18%	37.63%
Total Return (5Y, Annualized)	26.89%	23.78%

Risk Profile

Drawdown History

SMMT

UTHR

GSPC

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Summit Therapeutics (SMMT) and United Therapeutics (UTHR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. United Therapeutics (UTHR) has a non-negative beta of 0.49.

Risk profile metrics for Summit Therapeutics (SMMT) and United Therapeutics (UTHR)
Metric	SMMT	UTHR
Volatility (1Y, Annualized)	75.06%	35.00%
Beta (5Y)	-1.51	0.49
Max Drawdown (5Y)	-87.64%	-33.00%
Avg. Volume (3M)	6.19M	694.55K

Risk-Adjusted Performance

Risk-Return Positioning

SMMT and UTHR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Summit Therapeutics (SMMT) and United Therapeutics (UTHR)
Metric	SMMT	UTHR
Sharpe Ratio (1Y)	-0.09	0.70
Sortino Ratio (1Y)	-0.13	1.29

Profitability

ROE (TTM)

Summit Therapeutics (SMMT) reports a negative ROE of -220.01%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile United Therapeutics (UTHR) reports 19.13%, ranking against industry peers normally.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

-220.01%

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
SMMT: -220.01%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

United Therapeutics (UTHR) at 38.61% converts revenue to bottom-line profit above its industry’s benchmark range, while Summit Therapeutics (SMMT) at 0.00% keeps roughly the typical share for its industry.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 18.05%
Q3: 4.78%
SMMT: 0.00%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

United Therapeutics (UTHR) at 28.99% operates in the top operating margin quartile, ahead of Summit Therapeutics (SMMT) at 0.00%, which runs around its industry’s norm.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max: 83.12%
Q3: 14.77%
SMMT: 0.00%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Summit Therapeutics (SMMT) and United Therapeutics (UTHR)
Metric	SMMT	UTHR
ROE (TTM)	-220.01%	19.13%
ROA (TTM)	-111.99%	10.91%
Net Margin (TTM)	0.00%	38.61%
Operating Margin (TTM)	0.00%	28.99%
Gross Margin (TTM)	0.00%	86.34%

Growth

Revenue Growth

Only one side can be read here: United Therapeutics (UTHR) reports revenue growth of 10.61%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: United Therapeutics (UTHR) reports EPS growth of 13.07%, ranked against its industry; Summit Therapeutics (SMMT) has no EPS growth figure this period.

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Summit Therapeutics (SMMT) and United Therapeutics (UTHR)
Metric	SMMT	UTHR
Revenue Growth (YoY)	--	10.61%
Revenue Growth (3Y CAGR)	--	18.02%
EPS Growth (YoY)	--	13.07%
EPS Growth (3Y CAGR)	--	22.92%

Financial Strength

Current Ratio (MRQ)

Both Summit Therapeutics (SMMT) at 5.99 and United Therapeutics (UTHR) at 4.61 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.99

Max: 25.13
Q3: 12.13
SMMT: 5.99
Median: 5.52
Q1: 2.47
Min: 0.10

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Summit Therapeutics (SMMT) carries debt-to-equity ratio of 0.04 against its industry range, while United Therapeutics (UTHR) reports no figure this period.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.04

Max: 1.42
Q3: 0.65
Median: 0.15
SMMT: 0.04
Q1: 0.02
Min: 0.00

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): UTHR does not report debt-to-equity ratio, so it has no value marker; SMMT is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Summit Therapeutics (SMMT) and United Therapeutics (UTHR)
Metric	SMMT	UTHR
Current Ratio (MRQ)	5.99	4.61
Debt / Equity (MRQ)	0.04	--
Net Debt / EBITDA	--	-1.53

Dividends

Dividend Yield (TTM)

Neither Summit Therapeutics (SMMT) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Summit Therapeutics (SMMT) nor United Therapeutics (UTHR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

SMMT: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Summit Therapeutics (SMMT) and United Therapeutics (UTHR)
Metric	SMMT	UTHR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: United Therapeutics (UTHR) trades at 21.22 times trailing earnings, ranked against its peers, while Summit Therapeutics (SMMT) has no P/E ratio this period.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
SMMT: --

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): SMMT does not report P/E ratio, so it has no value marker; UTHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

A sales-based read is only available for United Therapeutics (UTHR), whose P/S ratio of 7.51 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
Min: 0.01
SMMT: --

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): SMMT does not report P/S ratio, so it has no value marker; UTHR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/B Ratio (MRQ)

United Therapeutics (UTHR) at 3.80 sits near its industry’s typical P/B ratio, while Summit Therapeutics (SMMT) at 23.13 prices above its benchmark range — SMMT looks rich relative to book.

SMMT

Pharmaceuticals, Biotechnology & Life Sciences industry group

23.13

SMMT: 23.13
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Summit Therapeutics (SMMT) vs. United Therapeutics (UTHR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Summit Therapeutics (SMMT) and United Therapeutics (UTHR)
Metric	SMMT	UTHR
P/E Ratio (TTM)	--	21.22
P/S Ratio (TTM)	--	7.51
P/B Ratio (MRQ)	23.13	3.80
Free Cash Flow Yield (TTM)	-1.64%	1.90%